Table 1.

Baseline Characteristic of included studies.

First author, year	Tumor types	Study design	Treatment arms	Sample size	Age	Gender	Efficacy outcomes reported	Safety outcomes reported
Liu et al. (22)	Relapsed/refractory Hodgkin lymphoma	Randomized phase II study	Camrelizumab	19	28 (18–44)	12/7	PFS, duration of response (DOR), ORR	Any grade, Grade 3–4
			Chemotherapy (Decitabine)+ camrelizumab	42	26 (12–66)	25/17
Zhou et al. (23)	Advanced non-squamous non-small-cell lung cancer (CameL)	Randomized, open-label, multicenter, phase III trial	Camrelizumab+ Chemotherapy (carboplatin+ pemetrexed)	205	59 (54–64)	146/59	PFS, OS, ORR	Any grade, Grade 3–4
			Chemotherapy (carboplatin+ pemetrexed)	207	61 (53–65)	149/58
Huang et al. (24)	Advanced or metastatic esophageal squamous cell carcinoma (ESCORT)	Multicenter, randomized, open-label, phase III study	Camrelizumab group	228	60 (54–65)	208/20	OS, PFS, DOR, ORR	Any grade, Grade 3–4
			Chemotherapy group	220	60 (54–65)	192/28
Nie et al. (25)	Relapsed/refractory Classical Hodgkin Lymphoma	Two-arm, open-label, phase II study	Camrelizumab	19			ORR	Any grade, Grade 3–4
			Chemotherapy (Decitabine)+ camrelizumab	25